ANI PHARMACEUTICALS INC (ANIP)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 350M 700M 1.1B Q1 '16: 78.1M Q2 '16: 89.9M Q3 '16: 108.5M Q4 '16: 128.6M Q1 '17: 144.7M Q2 '17: 158.1M Q1 '18: 186.7M Q2 '18: 189.2M Q3 '18: 191.7M Q4 '18: 201.6M Q1 '19: 208M Q2 '19: 215.1M Q3 '19: 215.7M Q4 '19: 206.5M Q1 '20: 203.4M Q2 '20: 197.5M Q3 '20: 199.2M Q4 '20: 208.5M Q1 '21: 213.2M Q2 '21: 213.4M Q3 '21: 212.5M Q4 '21: 216.1M Q1 '22: 226.1M Q2 '22: 251.3M Q3 '22: 283.1M Q4 '22: 316.4M Q1 '23: 358.7M Q2 '23: 401.4M Q3 '23: 449.4M Q4 '23: 486.8M Q1 '24: 517.5M Q2 '24: 539M Q3 '24: 555.5M Q4 '24: 614.4M Q1 '25: 674.1M Q2 '25: 747.4M Q3 '25: 826.9M Q4 '25: 883.4M Q1 '26: 923.7M Q2 '26: 978.4M Q1 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Gross Profit TTM

0 200M 400M 600M Q4 '20: 76.7M Q1 '21: 83.5M Q2 '21: 81.9M Q3 '21: 76.7M Q4 '21: 68.3M Q1 '22: 60.3M Q2 '22: 70.1M Q3 '22: 90.6M Q4 '22: 120.6M Q1 '23: 159.4M Q2 '23: 194.1M Q3 '23: 225.9M Q4 '23: 245.5M Q1 '24: 264.7M Q2 '24: 270.8M Q3 '24: 271.8M Q4 '24: 296.4M Q1 '25: 324M Q2 '25: 371.9M Q3 '25: 414.2M Q4 '25: 450.6M Q1 '26: 472.4M Q2 '26: 505.2M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income TTM

-120M -60M 0 60M 120M 180M Q1 '16: 28.8M Q2 '16: 25.6M Q3 '16: 25M Q4 '16: 20.1M Q1 '17: 19M Q2 '17: 20.8M Q1 '18: 30.2M Q2 '18: 30.5M Q3 '18: 31.3M Q4 '18: 35.4M Q1 '19: 33.2M Q2 '19: 35.3M Q3 '19: 32.5M Q4 '19: 16.4M Q1 '20: 4.1M Q2 '20: -16.5M Q3 '20: -21M Q4 '20: -16M Q1 '21: -5.1M Q2 '21: -9.4M Q3 '21: -15.7M Q4 '21: -39.8M Q1 '22: -62M Q2 '22: -59.4M Q3 '22: -60.8M Q4 '22: -35.3M Q1 '23: -6.2M Q2 '23: 19.1M Q3 '23: 42.1M Q4 '23: 47M Q1 '24: 57.4M Q2 '24: 50.2M Q3 '24: 11.7M Q4 '24: 584K Q1 '25: 6.5M Q2 '25: 15.2M Q3 '25: 71.9M Q4 '25: 111.1M Q1 '26: 123.8M Q2 '26: 150.4M Q1 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income TTM

-80M -40M 0 40M 80M 120M Q3 '14: 11.2M Q4 '14: 28.7M Q1 '15: 29.8M Q2 '15: 35.7M Q3 '15: 33.5M Q4 '15: 15.4M Q1 '16: 12.4M Q2 '16: 9.9M Q3 '16: 7.9M Q4 '18: 15.5M Q1 '19: 13.7M Q2 '19: 17.5M Q3 '19: 16.4M Q4 '19: 6.1M Q1 '20: -1.4M Q2 '20: -20.3M Q3 '20: -23.7M Q4 '20: -22.5M Q1 '21: -15.5M Q2 '21: -17.2M Q3 '21: -22.1M Q4 '21: -42.6M Q1 '22: -62.8M Q2 '22: -63.6M Q3 '22: -67.8M Q4 '22: -47.9M Q1 '23: -26.3M Q2 '23: -5.2M Q3 '23: 13.4M Q4 '23: 18.8M Q1 '24: 35.5M Q2 '24: 27M Q3 '24: -7.1M Q4 '24: -18.5M Q1 '25: -21M Q2 '25: -10.2M Q3 '25: 40.6M Q4 '25: 78.3M Q1 '26: 92.1M Q2 '26: 108.3M Q3 '15 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue TTM

0 150M 300M 450M Q1 '16: 13.4M Q2 '16: 22M Q3 '16: 35.4M Q4 '16: 48.8M Q1 '17: 61.8M Q2 '17: 71.1M Q1 '18: 83.3M Q2 '18: 78.8M Q3 '18: 73.3M Q4 '18: 73M Q1 '19: 67.1M Q2 '19: 66.1M Q3 '19: 65.5M Q4 '19: 63.2M Q1 '20: 70.2M Q2 '20: 75.3M Q3 '20: 80.4M Q4 '20: 87.2M Q1 '21: 85.3M Q2 '21: 87M Q3 '21: 91.3M Q4 '21: 100.6M Q1 '22: 114.9M Q2 '22: 127.9M Q3 '22: 136.4M Q4 '22: 138.8M Q1 '23: 142.2M Q2 '23: 149.2M Q3 '23: 164.4M Q4 '23: 181.5M Q1 '24: 193M Q2 '24: 208.4M Q3 '24: 223.3M Q4 '24: 250.2M Q1 '25: 274.1M Q2 '25: 291M Q3 '25: 321.3M Q4 '25: 341.3M Q1 '26: 361.9M Q2 '26: 387.4M Q1 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating Cash Flow TTM

-80M 0 80M 160M 240M Q3 '16: 20.1M Q4 '16: 27.5M Q1 '17: 23M Q2 '17: 19.7M Q3 '17: 35.7M Q4 '17: 39.4M Q1 '18: 55.8M Q2 '18: 64.4M Q3 '18: 55.6M Q4 '18: 67.1M Q1 '19: 58.4M Q2 '19: 54.6M Q3 '19: 68.1M Q4 '19: 45.6M Q1 '20: 33M Q2 '20: 49.2M Q3 '20: 25.8M Q4 '20: 15.3M Q1 '21: 34.2M Q2 '21: 13.6M Q3 '21: 9.8M Q4 '21: 3.3M Q1 '22: -36.3M Q2 '22: -48M Q3 '22: -39M Q4 '22: -31.2M Q1 '23: 9.2M Q2 '23: 41.3M Q3 '23: 69.8M Q4 '23: 119M Q1 '24: 115.8M Q2 '24: 112.6M Q3 '24: 92.9M Q4 '24: 64M Q1 '25: 80.7M Q2 '25: 139.1M Q3 '25: 170.7M Q4 '25: 185.2M Q1 '26: 208.6M Q2 '26: 189.5M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow TTM

-70M 0 70M 140M 210M Q3 '16: 15.8M Q4 '16: 22.9M Q1 '17: 17.7M Q2 '17: 12.8M Q3 '17: 27.4M Q4 '17: 29.1M Q1 '18: 45.3M Q2 '18: 55.1M Q3 '18: 47.5M Q4 '18: 61.3M Q1 '19: 53.2M Q2 '19: 48.8M Q3 '19: 62.1M Q4 '19: 39M Q1 '20: 26.7M Q2 '20: 43.7M Q3 '20: 20.1M Q4 '20: 9.1M Q1 '21: 28.9M Q2 '21: 8.1M Q3 '21: 5.5M Q4 '21: 765K Q1 '22: -40.1M Q2 '22: -52.2M Q3 '22: -45.1M Q4 '22: -40.1M Q1 '23: -113K Q2 '23: 30.8M Q3 '23: 60.1M Q4 '23: 110.1M Q1 '24: 104.7M Q2 '24: 99.5M Q3 '24: 76.8M Q4 '24: 47.8M Q1 '25: 66.6M Q2 '25: 125.4M Q3 '25: 155.7M Q4 '25: 171.4M Q1 '26: 191.2M Q2 '26: 173M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 8M 16M 24M Q3 '13: 9.5M Q1 '14: 10M Q2 '14: 11.2M Q3 '14: 11.3M Q1 '15: 11.6M Q2 '15: 11.5M Q3 '15: 11.6M Q1 '16: 11.5M Q2 '16: 11.5M Q3 '16: 11.6M Q1 '17: 11.7M Q2 '17: 11.7M Q2 '17: 11.7M Q3 '17: 11.7M Q1 '18: 11.7M Q2 '18: 11.8M Q3 '18: 11.8M Q1 '19: 11.8M Q2 '19: 12.3M Q3 '19: 12.1M Q1 '20: 11.9M Q2 '20: 12M Q3 '20: 12M Q1 '21: 12M Q2 '21: 12.1M Q3 '21: 12.1M Q1 '22: 16.1M Q2 '22: 16.3M Q3 '22: 16.3M Q1 '23: 16.5M Q2 '23: 17.9M Q3 '23: 19.1M Q1 '24: 19.4M Q2 '24: 19.3M Q3 '24: 19.4M Q1 '25: 20M Q2 '25: 20.3M Q3 '25: 21.1M Q1 '26: 21.5M Q2 '26: 21.9M Q1 '15 Q3 '16 Q1 '18 Q3 '19 Q2 '21 Q1 '23 Q3 '24 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-6.00 -4.00 -2.00 0.00 2.00 4.00 6.00 Q1 '16: 1.07 Q2 '16: 0.86 Q3 '16: 0.69 Q4 '16: 0.35 Q1 '17: 0.33 Q2 '17: 0.46 Q1 '18: -0.01 Q2 '18: -0.01 Q3 '18: 0.01 Q4 '18: 1.30 Q1 '19: 1.15 Q2 '19: 1.45 Q3 '19: 1.35 Q4 '19: 0.48 Q1 '20: -0.15 Q2 '20: -1.71 Q3 '20: -1.99 Q4 '20: -1.88 Q1 '21: -1.28 Q2 '21: -1.42 Q3 '21: -1.83 Q4 '21: -3.40 Q1 '22: -4.68 Q2 '22: -4.45 Q3 '22: -4.63 Q4 '22: -3.05 Q1 '23: -1.72 Q2 '23: -0.49 Q3 '23: 0.51 Q4 '23: 0.82 Q1 '24: 1.58 Q2 '24: 1.15 Q3 '24: -0.57 Q4 '24: -1.14 Q1 '25: -1.27 Q2 '25: -0.77 Q3 '25: 1.63 Q4 '25: 3.35 Q1 '26: 3.94 Q2 '26: 4.63 Q1 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.